Stockreport

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF G&A Expenses: $2.9 million in Q3 2024, compared to $2.7 million in Q3 2023. Cash Equivalents and Marketable Securities: $65.5 million as of September 30, 2024, down f [Read more]